News | August 06, 2025
Cadila Pharmaceuticals launches Vasograin Plus for treatment of migraines
Vasograin Plus represents a major advancement in the treatment of migraine
Vasograin Plus represents a major advancement in the treatment of migraine
The performance was below anticipated levels, primarily due to external factors such as seasonal disruption that affected overall results
India Formulation sales accounted for 34.2% of total consolidated sales for the quarter
The facility includes advanced laboratories to monitor market trends, consumer needs, product innovation, and formulation improvements
A global platform advancing pharmaceutical collaboration, innovation, and exports—powering healthcare and connecting markets worldwide
Torrent Pharmaceuticals has reported total income of Rs. 3,141 crores during the period ended June 30, 2025
He has previously served in pivotal HR leadership roles at RPG Life Sciences, Akumentis Healthcare, and Wockhardt
Aman holds a bachelor’s degree in economics from Boston University and an MBA from Columbia University, New York
Carbamazepine Extended-Release Tablets are indicated for use as an anticonvulsant drug
Net profit doubled to Rs. 10.8 crore, with PAT margin expanding by 560 bps to 14.3%, reflecting strong operational execution
Subscribe To Our Newsletter & Stay Updated
